Multiple myeloma (MM) accounts for 10% of all malignant hematologic neoplasms. There is a significant variation in the survival of patients with myeloma. Prognostic factors are needed to identify groups of patients with widely different survival rates to assist in counseling and therapeutic strategies. Studies have shown that serum levels of interleukin-6 (IL-6) have prognostic value in MM. The serum C-reactive protein (CRP) is an acute phase protein (APP) and has been proposed as a surrogate

more »

... rker for serum IL-6 levels. CRP has also prognostic value in myeloma (1-3). Background: C-reactive protein (CRP) is an acute phase protein (APP) and has prognostic significance in multiple myeloma (MM). Procalcitonin (PCT) is also an APP and has been reported to be elevated in patients with severe systemic infection and sepsis. Aims: We investigated PCT level in patients with MM and its relationship with the stage and activity of the disease. The discriminatory value of PCT level in myeloma patients with and without infection was also assessed.